2024
‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatients
2023
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Leapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGrade group 2 prostate cancerGleason Grade Group 1Risk prostate cancerGrade group 1Prostate cancer riskProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsGenomic test resultsConclusions PatientsInitial biopsyPhysician recommendationPatient knowledgePatient counsellingConventional content analysisCancer managementExpression testPatient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression test“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.Peer-Reviewed Original ResearchActive surveillanceProstate cancerProstate MRIPatient experienceGleason Grade Group 1Prostate cancer active surveillanceIntermediate-risk prostate cancerRisk prostate cancerGrade group 1Group 2 tumorsMRI-ultrasound fusion biopsyMean sample ageHispanics/LatinosInitial diagnosisFusion biopsyProstate biopsyConventional content analysisPatient's perspectiveClinical careGroup 1MRI resultsMRI scansProviders' explanationsCancerPatients
2017
Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation
Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIncremental cost-effectiveness ratioPrice reductionHealth care costsProbabilistic sensitivity analysesMarkov decision-analytic modelCost-effectiveness ratioIndication-specific pricingLife-time costsCare costsAutologous stem cell transplantationDecision analytic modelStandard discountingQALYBrentuximab vedotinHigher health care costsActive surveillancePricingConsolidative settingConsolidation therapyCostSensitivity analysis
2016
Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue
Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.Peer-Reviewed Original ResearchAutologous stem cell transplantationReconstructed individual patient dataIncremental cost-effectiveness ratioR Hodgkin lymphomaIndividual patient dataHodgkin's lymphomaActive surveillanceOverall survivalHealth care costsHL progressionHL recurrenceHealthcare costsCare costsHigh-risk Hodgkin lymphomaSignificant health care costsDouble-blind trialPatient dataUse of BVFirst-line therapyHigh-dose chemotherapyPrimary refractory diseaseProgression-free survivalStem cell rescueLong-term followStem cell transplantation